News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    

Clinical - Phase I
Enanta Pharmaceuticals, Inc. Initiates Phase 1 Clinical Study Of EDP-305, Its Lead FXR Agonist For The Treatment Of Non-Alcoholic Steatohepatitis (NASH) 9/29/2016
NW Bio (NWBO) Presents Further DCVax-Direct Phase I Trial Information On Individual Patient Survival At NY Cancer Immunotherapy Conference 9/29/2016
Cellectar Biosciences  (CLRB) Announces New Positive Data From Phase I Clinical Study Of CLR 131 In Multiple Myeloma 9/29/2016
Dermata Therapeutics Announces Positive Top-Line Results From Their Phase 1 Pharmacokinetic Study Of DMT210 In Acne Rosacea Patients 9/28/2016
Immune Design Corporation (IMDZ) Announces Advancement Of First GLAAS-Based Allergy Program Into Clinical Development 9/28/2016
Karyopharm (KPTI) Publishes Preclinical And Phase 1 Clinical Data For Selinexor In Ovarian Cancer In Clinical Cancer Research Publication 9/28/2016
Incyte (INCY) Release: Updated Phase 1 Data Reinforce The Clinical Profile Of Epacadostat In Combination With Keytruda (Pembrolizumab) 9/28/2016
BeyondSpring Pharmaceuticals Announces First Patient Enrolled In Phase 1b/2 Investigator-Initiated Trial Of Plinabulin Plus Nivolumab For Non-Small Cell Lung Cancer 9/27/2016
Asterias Biotherapeutics Announces Dosing Of First Patient In New SCiSTAR Clinical Trial Cohort Testing AST-OPC1 In An Expanded Cervical Spinal Cord Injury Patient Population 9/27/2016
X4 Pharma Announces Initiation Of Phase Ib Study Of X4P-001 In Patients With Resectable Stage III And Stage IV Melanoma 9/27/2016
Rich Pharma Announces Quarterly Milestones 9/27/2016
ARMO BioSciences Announces Data Presentations At The CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 9/27/2016
Fate Therapeutics (FATE) Receives FDA Orphan Drug Designation For Protmune In Allogeneic Hematopoietic Cell Transplantation 9/26/2016
Idera Pharma (IDRA) Reports Promising Data From Ongoing Phase I Dose Escalation In Clinical Trial Of Intra-Tumoral IMO-2125 In Combination With Ipilimumab In Patients With PD-1 Refractory Metastatic Melanoma 9/26/2016
Corvus Pharma Announces Preclinical And Preliminary Clinical Biomarker Data Of Lead Oral Checkpoint Inhibitor CPI-444 Presented At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 9/26/2016
SciClone (SCLN) Announces Progress In Advancing Clinical Pipeline For China Pharmaceuticals Market 9/26/2016
Dicerna (DRNA) Terminates Development of DCR-PH1, Shifts Focus 9/26/2016
Alnylam (ALNY) Reports Positive Initial Results From Ongoing Phase 1/2 Study Of ALN-GO1, An Investigational Rnai Therapeutic For The Treatment Of Primary Hyperoxaluria Type 1 9/26/2016
Aerpio Initiates Phase Ia Study Of AKB-4924, A First In Class Once-Daily, Orally Administered HIF-1 Stabilizer, In Development To Treat Inflammatory Bowel Disease (IBD) 9/26/2016
First Patient Dosed In CANBridge Life Sciences’s CAN-008 Phase I/II Trial In Newly-Diagnosed Glioblastoma Multiforme In Taiwan 9/26/2016
Faraday Pharma Announces First-In-Human Trial Of FDY-5301 9/23/2016
NW Bio (NWBO) Presents Updated Data From DCVax-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference In London 9/22/2016
First Patient Enrolled In Toca 6, Tocagen's Trial For Metastatic Cancers Evaluating Intravenously Delivered Toca 511 Virus 9/22/2016
Anaheim Clinical Trials (ACT) Completes Large Phase 1 Trial In Healthy Volunteers And Psoriasis Patients For Major Pharmaceutical Company 9/22/2016
Proteostasis (PTI) Announces Scientific Presentations On New Data At 30th Annual North American Cystic Fibrosis Conference 9/22/2016
Mirna Halts Clinical Study of Lead Drug After Patients Get Sick 9/21/2016
Children’s Of Alabama Seeking Patients For Innovative Phase 1 Trial For Pediatric Brain Tumor Patients 9/21/2016
Zafgen (ZFGN) Initiates Multiple Ascending Dose Cohorts In Phase I Clinical Trial Of ZGN-1061 9/20/2016
VBI Vaccines Completes Enrollment Of Participants In The Phase I Clinical Trial Of Its Preventative Cytomegalovirus Vaccine Candidate 9/20/2016
scPharmaceuticals Announces Presentations On Subcutaneous Furosemide At HFSA Annual Meeting 9/20/2016
AmpliPhi Bio (APHB) Provides Update On Phase I Trial In Chronic Rhinosinusitis Patients 9/20/2016
Bexion Pharmaceuticals Doses First Patient In Phase I Trial Of BXQ-350 For Patients With Advanced Solid Tumors At The University Of Cincinnati Cancer Institute 9/20/2016
MabVax Therapeutics Reports On Interim Progress On Its Programs Including The Phase I Clinical Trial For Therapeutic Antibody Treatment Of Pancreatic Cancer 9/19/2016
Fibrocell (FCSC) Completes Enrollment In NC1+ Cohort Of Phase I/II Clinical Trial Of FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 9/19/2016
China Biologic Products Receives CFDA Clinical Trial Approval For Human Coagulation Factor IX 9/19/2016
UK Regulatory Authority Approves Cynata GvHD Clinical Trial 9/19/2016
Parkinson’s Disease: Prexton Therapeutics Completes Phase 1 Clinical Trial 9/19/2016
Corvus PharmaTo Present Data On Lead Oral Checkpoint Inhibitor CPI-444 At Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference 9/19/2016
Infinity Pharma (INFI) Announces Publication On PI3K-Gamma In Nature 9/19/2016
Seattle Genetics (SGEN) Initiates Phase I Trial Of SGN-CD123A For Patients With Relapsed Or Refractory Acute Myeloid Leukemia 9/19/2016
Gilead (GILD) to Release Data on 9 Clinical Trials Before End of the Year 9/16/2016
Xencor Initiates Phase 1b Trial Of Subcutaneous Formulation Of Xmab7195 9/15/2016
Zymeworks Doses First Patient In Phase I Trial Of ZW25, A Novel Bi-Specific Antibody For The Treatment Of HER2-Expressing Cancers 9/15/2016
Xenikos: Last Patient Treated In Phase 1/2 Trial With T-Guard In Acute Graft-Versus-Host Disease 9/15/2016
Viamet Release: FDA Grants QIDP Designation To VT-1598 For Treatment Of Valley Fever 9/15/2016
Allakos Begins Clinical Trials Of AK002 In Patients With Systemic Mastocytosis 9/15/2016
Asterias Biotherapeutics AST-OPC1 Treatment For Spinal Cord Injury Patients Shown To Help Patients Paralyzed From The Neck Down Regain Function In The Arms And Hands 9/14/2016
Heat Biologics Resumes Enrollment In Its Non-Small Cell Lung Cancer Trial Evaluating HS-110 In Combination With Anti-PD-1 Checkpoint Inhibitor 9/14/2016
GlycoMimetics, Inc. (GLYC) Doses First Patient In Phase 1 Clinical Trial Of Drug Candidate GMI-1271 For Multiple Myeloma 9/14/2016
10 Biotechs—Count ‘Em, 10!—With Big Decisions in the Fourth Quarter 9/13/2016
Kezar Life Sciences Announces Initiation Of Phase 1 Clinical Program For Lead Candidate KZR-616, A First-In-Class Immunoproteasome Inhibitor 9/13/2016
Aphios To Develop HIV/AIDS Cure Using Combination Drugs In Targeted ‘Nanosomes’ Nanoparticles 9/13/2016
Inotrem Successfully Completes Its First Phase I Clinical Trial With Motrem, A TREM-1 Pathway Modulator For The Treatment Of Septic Shock 9/13/2016
AmpliPhi Bio (APHB) Announces Topline Results From Its Phase I Phage Therapy Trial Conducted In The United States 9/13/2016
Amplyx Initiates Dosing In Phase 1 Clinical Trial Of APX001, A Novel Antifungal Product Candidate For Treatment Of Life-Threatening Infections 9/12/2016
Celgene (CELG) Touts Early Stage Crohn’s Disease Data 9/12/2016
Xencor Doses First Patient In Lead Immuno-Oncology Bispecific Program Xmab14045 For The Treatment Of Acute Myeloid Leukemia And Other CD123-Expressing Hematologic Malignancies 9/12/2016
Sunesis (SNSS) Presents Dose Escalation Results From The Phase IA Healthy Volunteer Study Evaluating Oral Non-Covalent BTK Inhibitor SNS-062 9/12/2016
MGB Biopharma Limited Granted Qualified Infectious Disease Product (QIPD) Designation By U.S. FDA For The Treatment Of Clostridium Difficile-Associated Diarrhoea (CDAD) For MGB-BP-3 9/12/2016
AmpliPhi Bio (APHB)’ Bacteriophage Cocktail Shown To Prevent C. difficile Biofilm Formation And Reduce Colonization 9/12/2016
Celgene (CELG) Announces Interim Topline Data From Trial Of Investigational Oral GED-0301 In Patients With Active Crohn’s Disease 9/12/2016
Tobira (TBRA) Announces Initiation Of Phase I Combination Study of Cenicriviroc And Evogliptin 9/12/2016
Juno (JUNO) Surges as Small Cancer Study is Hailed a Success, Shows Promise for Other Drugs 9/9/2016
Avelas Biosciences Completes Patient Enrollment For AVB-620 Phase 1b Clinical Trial 9/8/2016
La Jolla Pharma (LJPC) Reports Positive Results From Phase 1 Study Of LJPC-401 9/8/2016
La Jolla Pharma (LJPC) Announces Agreement With EMA On Pivotal Study Of LJPC-401 9/8/2016
RedHill Biopharma (RDHL) Announces Phase Ib/II Study With YELIVA Initiated For Multiple Myeloma At A Leading U.S. Academic Medical Center 9/8/2016
GTx, Inc. (GTXI) Achieves Stage 1 Milestone In Phase II Clinical Trial Of Enobosarm In ER+/AR+ Breast Cancer 9/8/2016
Capricor Therapeutics, Inc. Completes Enrollment In Randomized HOPE Clinical Trial In Duchenne Muscular Dystrophy 9/7/2016
BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications 9/7/2016
Boost Vaccination Data Encourage Continued Development of AFFiRiS AG Therapeutic Parkinson's Disease Vaccine Against Alpha-Synuclein 9/7/2016
Edge Therapeutics Announces Additional Pharmacokinetic Data Supporting The Potential Clinical And Health Economic Impact Of EG-1962 In Aneurysmal Subarachnoid Hemorrhage 9/7/2016
Alnylam (ALNY) Reports Positive Interim Results From Ongoing Phase I Study Of ALN-AS1, An Investigational Rnai Therapeutic For The Treatment Of Acute Hepatic Porphyrias 9/7/2016
Proclara Announces Initiation Of Phase Ib Clinical Trial Of NPT088 For Alzheimer’s Disease 9/7/2016
Arrowhead Pharma (ARWR) Doses First Patient With Hepatitis B In Multiple Ascending Dose Portion Of Phase I/II Study Of ARC-521 9/7/2016
Sensorion Announces Positive Results From SENS-218 Phase I Clinical Trial Undertaken In The UK 9/7/2016
GlycoMimetics, Inc. (GLYC) Initiates Dosing In Phase I Clinical Trial Of GMI-1359 9/6/2016
Peloton Therapeutics Announces Dual Publications Of HIF-2a Antagonism In Kidney Cancer In The Journal Nature 9/6/2016
Sangamo (SGMO) Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing 9/6/2016
Biogen (BIIB)’s Shares Rise After FDA Fast Tracks Alzheimer’s Drug 9/2/2016
Oncotelic And Autotelic Announce Clinical Data Supporting IL-8 Spike As A Prognostic Biomarker For Immunotherapy 9/2/2016
Edge Therapeutics To Present Additional Data From Phase I/II NEWTON Study Of EG-1962 At Two Scientific Conferences In September 9/2/2016
Biogen (BIIB)'s Experimental Alzheimer’s Drug Shows Promise in Human Trials 9/1/2016
Viking Therapeutics (VKTX) Presents Phase 1 Data And Highlights Ongoing Phase 2 Study Of VK5211 At 5th Fragility Fracture Network Global Congress 2016 9/1/2016
GenSight Biologics Receives Orphan Drug Designation And Advanced Therapy Medicinal Product Classification In Europe For GS030 In Retinitis Pigmentosa 9/1/2016
Fibralign Announces Enrollment Initiated For Stanford University-Led Clinical Trial For Breast Cancer-Related Lymphedema 9/1/2016
InCarda Initiates Enrollment Of Phase 1 Clinical Trial Of Inhaled Flecainide For The Treatment Of Cardiac Arrhythmias 8/31/2016
Asterias Biotherapeutics Receives Safety Clearance To Begin Administering The Highest Dose Of AST-OPC1 In The SCiStar Phase 1/2a Clinical Trial In Cervical Spinal Cord Injury Patients 8/31/2016
Neurimmune Therapeutics Release: Early Results Show Aducanumab Removes Amyloid Plaques In Patients With Alzheimer’s Disease 8/31/2016
Oncternal Therapeutics Initiates Patient Dosing In Phase 1 Clinical Trial Of TK216 In Ewing Sarcoma 8/30/2016
Syros Pharma’s Scientific Founders Publish On First Selective CDK12 And CDK13 Inhibitor As Promising Approach For Treatment Of Cancer 8/30/2016
Gradalis Inc. Announces Dosing Of First Patient In Pilot Study Combining Vigil Engineered Autologous Tumor Cell Immunotherapy And Durvalumab In Advanced Breast Cancer 8/29/2016
Abeona Therapeutics Completes Enrollment Of Low-Dose Cohort For ABO-102 In Phase 1/2 Clinical Trial For MPS IIIA Patients 8/29/2016
BirchBioMed Announces Completion Of Clinical Trial For Ground-Breaking Anti-Scarring Drug 8/26/2016
Pivotal Study Results Published In The New England Journal of Medicine Confirm Safety And Efficacy Of InSightec's Exablate Neuro System For The Treatment Of Essential Tremor 8/25/2016
Prima Biomed (PRR.AX): Operational Update 8/19/2016
A Look at Amgen (AMGN)'s Pipeline: Will it Help the Company Grow? 8/19/2016
ScarX Therapeutics Announces Approval For Trial Of First Clinically-Promising Scar Reduction Cream 8/18/2016
Zymeworks’ ZW25 And ZW33 Granted Orphan Drug Designation for Ovarian Cancer By U.S. FDA 8/18/2016
Karos Pharmaceuticals Announces Major Milestone Events 8/18/2016
New First-in-Pediatrics Trial At Children's Hospital Los Angeles To Test AstraZeneca Pharmaceuticals LP (AZN)'s Durvalumab For Certain Cancers 8/18/2016
Audentes (BOLD) Announces First Patient Enrolled In The INCEPTUS Clinical Assessment Study Of XLMTM 8/17/2016
Evofem Announces First Patient Enrolled In A Clinical Trial To Determine The Effect And Duration Of Amphora Gel On Vaginal Ph 8/17/2016
ARMO BioSciences Announces Publication Of AM0010 Clinical Data In Advanced Solid Tumor Patients In Journal Of Clinical Oncology (JCO) 8/16/2016
Regen BioPharma Receives New Preliminary HemaXellerate Clinical Data On Bone Marrow Suppression From Pan Am Cancer Treatment Center 8/16/2016
AbGenomics Corporation Announces FDA Acceptance To Commence Phase I Clinical Trial Of Abgn-107 ADC Candidate For Pancreatic, Gastric, And Colorectal Cancer Treatments 8/15/2016
FDA: Toxicity Seen In Fatal French Study Does Not Extend To Other FAAH Inhibitors 8/15/2016
Sun BioPharma Announces Completion Of The Second Patient Cohort And Starts Recruitment Of Third Cohort Patients In The Dose Escalation Phase 1 Study Of SBP101 For Pancreatic Cancer 8/15/2016
Results From Phase 1 Trials With Ligand (LGND)’s LGD-6972 In Type 2 Diabetes Mellitus Published In Diabetes, Obesity And Metabolism 8/15/2016
Tivorsan Pharmaceuticals, Inc. Granted FDA Orphan Drug Designation For Human Recombinant Biglycan In The Treatment Of Duchenne Muscular Dystrophy 8/15/2016
Fractyl’s Revita DMR Significantly Improves Hyperglycemia In Type 2 Diabetes Patients 8/12/2016
Vigilant Biosciences Awarded Phase I SBIR Grant For Next Generation Oral Cancer Diagnostic System 8/11/2016
KalVista Pharmaceuticals Announces Initiation Of A Phase 1 Clinical Trial Of KVD818 For The Treatment Of Hereditary Angioedema 8/11/2016
SAb Biotherapeutics Release: Phase I Clinical Trials Underway For First MERS Treatment 8/11/2016
Biocryst (BCRX) Announces Initiation Of The Apex-1 Clinical Trial Of BCX7353 For Hereditary Angioedema 8/11/2016
Inovio Pharma (INO) Expands Positive Phase I Ebola Vaccine Trial To Identify Most Optimal Immunization Regimen 8/11/2016
Protalix Biotherapeutics, Inc. (PLX) Announces Additional Positive Data From Its Phase I/II Clinical Trial For PRX-102 For The Treatment Of Fabry Disease 8/10/2016
RetroSense Therapeutics Completes Low Dose Cohort In Clinical Trial Of Novel Gene Therapy Application Of Optogenetics 8/10/2016
TARIS Biomedical Launches Second Phase 1b Clinical Trial Of TAR-200 (Gemris) In Patients With Bladder Cancer 8/10/2016
Amphivena Therapeutics Announces Acceptance Of Investigational New Drug (IND) Application For AMV564 And Planned Phase 1 Trial Initiation 8/10/2016
Novartis AG (NVS)'s New Asthma Drug Hailed a Game-Changer After Success in Small Trial 8/9/2016
Can-Fite BioPharma (CFBI)'s Phase II/III Psoriasis Study Results Published In Journal Of Drugs In Dermatology 8/8/2016
Pfenex (PFNX) Announces Positive Anthrax Vaccine Study Results 8/8/2016
San Diego’s Pfenex (PFNX) Regains Full Rights to PF582 and Announces Phase I/II Results 8/8/2016
Vaxart Challenges Takeda (TKPYY) with Oral Norovirus Vaccine 8/8/2016
Intec Pharma To Pursue Development Of Accordion Pill For Cannabinoid Therapies 8/4/2016
Evotec AG (EVTG.F) Achieves Clinical Development Milestone As Part Of Its Multi-Target Alliance With Bayer (BAY) In Endometriosis 8/4/2016
AmpliPhi Bio (APHB) Completes Enrollment Of Its Investigational Phage Therapy Trial Targeting Staphylococcus Aureus 8/3/2016
ColonaryConcepts Initiates Phase I Study Of New Approach To Treating Chronic Constipation 8/3/2016
ContraVir Reports Positive Data From Phase 1b Study Of CMX157 8/2/2016
Vaxart Initiates Clinical Development Of First Oral Norovirus Vaccine 8/2/2016
EyeGate Pharma Announces Positive Top-Line Data From Phase Ib/IIa Clinical Trial Of EGP-437 For Treatment Of Post-Operative Inflammation And Pain In Cataract Surgery Patients 8/1/2016
Asterias Biotherapeutics To Report Second Quarter Results On August 15, 2016 8/1/2016
TetraPhase (TTPH) Initiates Phase I Clinical Trial For TP-6076, A Second-Generation Antibiotic Candidate Highly Active Against MDR Bacteria 8/1/2016
Autifony Therapeutics Successfully Completes Phase I Study Of AUT00206, A First-In-Class Kv3 Modulator For Schizophrenia 8/1/2016
The Results Of Phase I Clinical Trial Of The Araclon Biotech Alzheimer's Vaccine Support Its Continuation 8/1/2016
TRACT Therapeutics Presents Follow-Up Phase I Clinical Data In Kidney Transplant Recipients At The American Transplant Congress 2016 7/29/2016
AstraZeneca PLC (AZN) Kills Six Pipeline Programs 7/28/2016
BioMarin (BMRN)'s Gene Therapy Yields Dramatic Results in Early Stage Hemophilia Study 7/28/2016
Protagonist Therapeutics Receives SBIR Funding For The Development Of Injectable Hepcidin Mimetics For Treatment Of Iron Overload Disorders 7/28/2016
Fibrocell (FCSC) Announces First Subjects Enrolled In Phase I/II Clinical Trial Of FCX-007 For Treatment Of Recessive Dystrophic Epidermolysis Bullosa 7/28/2016
uniQure (QURE) Presents Updated Clinical Data In Patients With Severe Hemophilia B Demonstrating Up To 9 Months Of Sustained Levels Of Factor IX Activity And Therapeutic Effect 7/28/2016
Nektar Therapeutics (NKTR) To Announce Financial Results For The Second Quarter 2016 On Wednesday, August 3, 2016, After Close Of U.S.-Based Financial Markets 7/28/2016
Corium International, Inc. Presents Full Clinical Results From Phase 1 Pharmacokinetic Study Of Once-Weekly Corplex Donepezil Transdermal System 7/28/2016
Regulus (RGLS) Provides Update On Clinical Hold Of RG-101 7/28/2016
Adaptimmune (ADAP) Receives Access To Priority Medicines (PRIME) Regulatory Support For Its SPEAR T-Cell Therapy Targeting NY-ESO For Treatment Of Soft Tissue Sarcoma 7/28/2016
Agenus (AGEN) Reports Second Quarter 2016 Financial Results And Operational Progress 7/28/2016
Genelux Initiates Two Clinical Trials Of GL-ONC1 In Ovarian Cancer And Solid Organ Cancers With Leading Oncology Institutions 7/28/2016
Stemedica Cell Technologies, Inc. Begins First Clinical Trials In The U.S. Using Adult Allogeneic Stem Cells To Treat Alzheimer's Disease 7/27/2016
Karyopharm (KPTI) Announces Phase Ib Selinexor Sarcoma Data Published In Journal Of Clinical Oncology 7/27/2016
Gamida Cell Announces First Patient With Sickle Cell Disease Transplanted In Phase 1/2 Study Of Cordin As The Sole Graft Source 7/27/2016
Seattle Genetics (SGEN) Reports Second Quarter 2016 Financial Results 7/27/2016
Bavarian Nordic (BAVA.CO) Announces Initiation Of NIH Sponsored Phase 1 Trial Of MVA-BN-based Yellow Fever Vaccine 7/27/2016
Flugen, Inc. Initiates A Phase I Clinical Trial Of The Redeeflu Universal Influenza Vaccine In Healthy Subjects 7/27/2016
Symcel Secures Phase I Horizon 2020 Grant As The Company Plans For Full Scale Commercialisation Of calScreener – The World’s First Multi Channel Calorimetry System For Antimicrobial Susceptibility Testing 7/27/2016
Adaptimmune (ADAP) Receives Orphan Drug Designation In The European Union For Its NY-ESO SPEAR T-Cell Therapy For Treatment Of Soft Tissue Sarcoma 7/26/2016
Eisai Inc. (ESALF.PK) And Halozyme (HALO) Initiate Phase 1b/2 Clinical Trial With First Patient Dosing Of Eribulin In Combination With PEGPH20 7/26/2016
Janssen Biotech (JNJ) Announces Clinical Collaboration With Bristol-Myers Squibb (BMY) To Evaluate Immuno-Oncology Combination In Lung Cancer 7/26/2016
Inovio Pharma (INO) Doses First Subject In Zika Vaccine Clinical Trial 7/26/2016
Advaxis (ADXS) Release: Phase I/II Combination Trial Of AXAL And Durvalumab Completes Second Dose-Escalation Cohort 7/26/2016
CANBridge Life Sciences’s CAN-008 Approved For Phase I/II Trial In Newly-Diagnosed Glioblastoma Multiforme In Taiwan 7/26/2016
GamaMabs Pharma SA Starts Phase Ia/Ib Study Of First-In-Class Monoclonal Antibody GM102 In Advanced Gynecological Cancer 7/26/2016
Opthea To Host Conference Call Providing Update On Phase 1 Wet AMD Clinical Trial With OPT-302 7/26/2016
FDA Lifts Clinical Hold on GenVec (GNVC)'s Hearing Loss Candidate 7/25/2016
Guardant Health Collaborates With OncoMed (OMED) On Anti-RSPO3 Clinical Trial 7/25/2016
Halozyme (HALO) Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Trial With KEYTRUDA 7/25/2016
ImmunoCellular Therapeutics, Ltd (IMUC) Reports Progress In Two Lead Cancer Immunotherapy Programs 7/25/2016
NewLink Genetics (NLNK) Announces Merck & Co. (MRK) Receives Breakthrough Therapy Designation From FDA And PRIME Status From EMA For Investigational Ebola Zaire Vaccine (V920) 7/25/2016
First Subject Treated In Zosano (ZSAN)'s Pivotal Efficacy Trial For M207 Patch For Acute Migraine 7/25/2016
KaloBios (KBIO) Announces First Patient Dosed In Phase I Study Of Lenzilumab For The Treatment Of Chronic Myelomonocytic Leukemia 7/25/2016
Alnylam (ALNY) To Report New Clinical Results With Fitusiran At The World Federation of Hemophilia 2016 World Congress 7/25/2016
FDA Grants QIDP And Fast Track Designations To MCB3837, Morphochem AG’s Novel Intravenous Antibacterial To Treat C. Difficile Infections 7/25/2016
Alnylam (ALNY) Announces New Positive Interim Phase I Study Results For Fitusiran, A Once-Monthly, Subcutaneous, Investigational Rnai Therapeutic Targeting Antithrombin For The Treatment Of Hemophilia And Rare Bleeding Disorders 7/25/2016
FDA Calls Pfizer (PFE), Spark Therapeutics (ONCE)'s Hemophilia B Drug a Breakthrough 7/22/2016
ViaCyte Awarded New CIRM Grant To Develop PEC-Direct For High-Risk Type 1 Diabetes 7/22/2016
Resverlogix (RVX.TO) Announces Dosing Of First Two Patients In Expanded Renal And Orphan Programs 7/22/2016
BioPharmX Study Shows BPX-01 Topical Gel Delivers Minocycline Precisely To The Skin 7/21/2016
TRANSGENE (ENX:TNG) To Continue Phase I/Ib Study With TG1050 In Chronic Hepatitis B Patients On The Recommendation Of The Trial’s Safety Review Committee 7/21/2016
AveXis' Spine Therapy Wins Breakthrough Tag From the FDA 7/20/2016
Pulmatrix And Mylan (MYL) Report Positive Pharmacokinetic Bioavailability Data In Pilot Study Of PUR0200 In Patients With Chronic Obstructive Pulmonary Disease (COPD) 7/19/2016
ProQR Therapeutics B.V. (PRQR) Receives Fast Track Designation From FDA For QR-010 For Cystic Fibrosis 7/19/2016
Cytori Therapeutics (CYTX) Cell Therapy Phase I Trial Reports Maxillofacial Bone Regeneration 7/19/2016
Navidea (NAVB) Receives IRB Approval For Its Lymphoseek Rheumatoid Arthritis Clinical Trial Protocol 7/19/2016
Updated Data For Epacadostat, Incyte (INCY)’s Selective IDO1 Inhibitor, Accepted For Presentation At The ESMO Annual Congress 2016 7/19/2016
Symcel Release: Initial €50,000 Phase 1 Grant Will Fund Full Feasibility Study 7/18/2016
GlaxoSmithKline (GSK) Becomes First Drug Firm to Use Apple (AAPL)’s ResearchKit for Clinical Research 7/18/2016
ZIOPHARM Abandons $50 Million Stock Offering After Clinical Trial Deaths 7/18/2016
MabVax Therapeutics Initiates Patient Enrollment In A Phase I Trial For A New Diagnostic Imaging Product For Pancreatic Cancer 7/18/2016
Champions Oncology, Inc. (CSBR) Successfully Delivers First AML Study 7/18/2016
Bexion Pharmaceuticals Receives FDA Clearance For The First Clinical Trial Using BXQ-350 To Dose Patients With Cancer 7/18/2016
With Little Fanfare, Biogen (BIIB) Sneaks Lupus Drug Into a Phase I Trial 7/15/2016
Armagen Presents Data From First Cohort Of Phase 1/2a Of AGT-182 For Treatment Of Hunter Syndrome 7/15/2016
ProtoKinetix Inc. (PKTX.OB)’ 2nd Quarter Scientific Update 7/14/2016
Alexion (ALXN) Presents New SBC-103 (rhNAGLU Enzyme) Phase I/II Data On Brain MRI And Neurocognitive Assessments In Patients With Mucopolysaccharidosis IIIB (MPS IIIB) 7/14/2016
Celyad Successfully Completes Safety Follow-Up Of The First Patient At The Fourth Dose Level In The NKR-2 Phase I Trial 7/14/2016
Oncternal Therapeutics' TK216 Receives Orphan Drug Designation For The Treatment Of Ewing Sarcoma, A Rare Pediatric Cancer 7/13/2016
Aptinyx Initiates Dosing In Phase 1 Clinical Study Of Lead NMDA-Receptor Modulator, NYX-2925 7/13/2016
Enteris Biopharma Initiates Clinical Program For Tobrate (Oral Tobramycin Tablet) In Uncomplicated Urinary Tract Infection 7/13/2016
TARIS Biomedical Initiates Phase Ib Clinical Trial Of TAR-200 (Gemris™) In Patients With Muscle-Invasive Bladder Cancer 7/13/2016
Oncodesign SA Announces The Launch Of Its First Clinical Study On A Radiotracer In Patients With Non-Small Cell Lung Cancer 7/13/2016



//-->